Washington, D.C.–Republican leaders of the Senate
and House Committees with oversight of the Centers for Medicare and Medicaid
Services (CMS) are raising concerns with a recent decision to severely restrict
coverage of a U.S. Food and Drug Administration (FDA)-approved Alzheimer’s
treatment and any similar future treatments,
in a disturbing break with precedent.
In a letter
to CMS, Senate Finance Committee Ranking Member Mike Crapo (R-Idaho), Senate
Health, Education, Labor and Pensions Ranking Member Richard Burr (R-North
Carolina), House Ways and Means Republican Leader Kevin Brady (R-Texas) and
House Energy and Commerce Republican Leader Cathy McMorris Rodgers (R-Washington)
outline how the decision departs from precedent and creates dire new concerns,
and ask for information on how CMS arrived at its decision.
From the letter:
“On various fronts, the national coverage determination
issued by the agency strays from precedent, subordinates the clinical judgment
and expertise of the Food and Drug Administration, and suggests a problematic
new standard that risks chilling innovation and jeopardizing access to the
cutting-edge treatments of the future. We urge CMS to reconsider this
approach and to operate within the bounds of its statutory authorities and
directives, which this latest decision oversteps.”
The members outline a number of problems with the final
decision, including that:
- CMS has never before
restricted Medicare access (through CED) to an FDA-approved indication
(use) of a drug or biologic.
- The decision restricts
access to an entire class of FDA-approved drugs based on a single drug’s
clinical trial results.
- CMS’s decision inappropriately
supplants FDA’s authority and exceeds its own.
- Under the decision, many
beneficiaries will receive a placebo, and some may even need to pay
cost-sharing for it.
- CMS has never before disadvantaged
drugs approved via FDA’s accelerated approval pathway, which has led
to hundreds of approvals for drugs treating cancer, HIV/AIDS, and other
life-threatening conditions. The decision risks deterring and
eroding the pathway, meaning delayed access to treatments.
- Full-benefit dually
eligible (Medicaid and Medicare) beneficiaries will have no access to
these drugs outside of the stringent CED standards, even though other
Medicaid enrollees will have access to these products (potentially subject
to utilization management).
- This decision could chill
investment in high-risk R&D, particularly for Alzheimer’s
treatments.
Full text of the letter is available here.